|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||365.55 - 365.55|
|52 Week Range||340.10 - 466.14|
|Beta (5Y Monthly)||0.28|
|PE Ratio (TTM)||20.01|
|Forward Dividend & Yield||9.97 (2.68%)|
|Ex-Dividend Date||Mar 17, 2022|
|1y Target Est||N/A|
Roche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe. The FDA approves expanded use of Lilly's (LLY) cancer drug, Retevmo.
Novartis (NVS) is looking to defend its patents for the multiple sclerosis drug Gilenya and file a petition in the Supreme Court after an unfavorable ruling in the federal court.
The European Commission approves Roche's (RHHBY) Vabysmo for treating neovascular or wet age-related macular degeneration and visual impairment due to diabetic macular edema.